INDICATIONS FOR USE

LL-37 is a synthetic version of a naturally occurring antimicrobial peptide (AMP) in the human innate immune system. It is used off-label to enhance immune defense, treat chronic infections, and reduce inflammation. It is also explored for its role in wound healing, autoimmune disorders, and biofilm disruption in resistant bacterial infections.

ROUTE OF ADMINISTRATION

• Topical: Applied directly to the skin or scalp as a cream, serum, or gel.

• Injectable: Administered subcutaneously near the affected area or target site for deeper tissue effects.

COMMON INITIAL DOSING REGIMENS

• Topical: Applied to the affected area 1–2 times daily. Concentrations in topical formulations are often customized but typically range from 0.1% to 0.5%.

• Injectable: A common protocol involves subcutaneous injections of 100–300 mcg daily or every other day for 2–4 weeks, depending on the condition treated. Maintenance dosing may be prescribed based on the response and clinical need.

MECHANISM OF ACTION

• LL-37 exerts antimicrobial, immunomodulatory, and wound-healing effects. It disrupts bacterial membranes by forming pores, making it highly effective against Gram-positive and Gram-negative bacteria, fungi, and some viruses. LL-37 also modulates immune cell activity by suppressing pro-inflammatory cytokines (e.g., IL-6, TNF-α) and enhancing anti-inflammatory pathways.

• In wound healing, LL-37 promotes angiogenesis and epithelialization by activating fibroblasts and keratinocytes. Its role in breaking down biofilms—a protective matrix formed by bacteria—makes it especially effective in treating chronic infections resistant to conventional antibiotics.

COMMON SIDE EFFECTS

• Localized Reactions: Mild redness, swelling, or itching at the injection site.

• Systemic Reactions: Transient fatigue, headache, or flu-like symptoms in rare cases.

• Immune Effects: Overactivation of the immune system can cause exacerbation of autoimmune conditions in susceptible individuals.

• Rare Effects: Allergic reactions, such as rash or difficulty breathing, though infrequent, should be monitored.

CONTRAINDICATIONS

• Absolute: Hypersensitivity to LL-37 or any excipient.

• Relative: Use with caution in patients with active autoimmune diseases, as LL-37 may exacerbate immune dysregulation. Limited safety data in pregnancy and breastfeeding advises against its use in these populations.

ADDITIONAL NOTES ON EFFICACY

• LL-37 is a versatile peptide with applications extending beyond dermatology to systemic immune support and inflammation control. In hair restoration protocols, it is often paired with growth factors or other peptides like GHK-Cu to maximize follicular stimulation.

COMPARISON WITH THYMOSIN ALPHA-1

• LL-37 and Thymosin Alpha-1 both modulate the immune system but differ in their primary mechanisms and applications. LL-37 focuses on antimicrobial effects and biofilm disruption, making it highly effective in infections and wound healing. Thymosin Alpha-1, on the other hand, boosts T-cell activity and immune regulation, with broader applications in viral infections, cancer immunotherapy, and vaccine enhancement.

• While LL-37 directly combats pathogens, Thymosin Alpha-1 strengthens host defenses, particularly against chronic infections and immune suppression. Their complementary mechanisms may allow combined use in conditions involving both immune dysfunction and chronic infection.

MORE INFORMATION

• FDA Safety Data Sheet not available (experimental peptide).

• Keshri AK. LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity. Int J Antimicrob Agents. 2025 [PubMed Link]

• Svensson D. Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update. Inflamm Res. 2025 [PubMed Link]

• Pahar B. Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections. Vaccines (Basel). 2020 [PubMed Link]

• Fabisiak A. LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. Pharmacol Rep. 2016 [PubMed Link]

• Xhindoli D. The human cathelicidin LL-37--A pore-forming antibacterial peptide and host-cell modulator. Biochim Biophys Acta. 2016 [PubMed Link]

• Chen K. The potentials of short fragments of human anti-microbial peptide LL-37 as a novel therapeutic modality for diseases. Front Biosci (Landmark Ed). 2021 [PubMed Link]

• Acen EL. Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: A systematic review and meta-analysis. PLoS One. 2021 [PubMed Link]

• Nagaoka I. Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model. Int J Mol Sci. 2020 [PubMed Link]

• Miao S. Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease. Pharmacol Res. 2024 [PubMed Link]

• Vera-Cruz A. Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent. Clin Invest Med. 2021 [PubMed Link]

• Aloul KM. Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis. Front Immunol. 2022 [PubMed Link]

• Zhang M. The Critical Role of the Antimicrobial Peptide LL-37/ CRAMP in Protection of Colon Microbiota Balance, Mucosal Homeostasis, Anti-Inflammatory Responses, and Resistance to Carcinogenesis. Crit Rev Immunol. 2019 [PubMed Link]

• Piktel E, Niemirowicz K, Wnorowska U, Wątek M, Wollny T, Głuszek K, Góźdź S, Levental I, Bucki R. The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz). 2016 [PubMed Link]

• Memariani M, Memariani H. Antifungal properties of cathelicidin LL-37: current knowledge and future research directions. World J Microbiol Biotechnol. 2023 [PubMed Link]

• Memariani H, Memariani M. Antibiofilm properties of cathelicidin LL-37: an in-depth review. World J Microbiol Biotechnol. 2023 [PubMed Link]